On March 8, more than 40 Cystic Fibrosis Foundation volunteers from across the nation came together on Capitol Hill to speak out on behalf of their friends and family members with cystic fibrosis.
Site Search
The U.S. House of Representatives and the Senate have both incorporated the Expanding and Promoting Expertise in Review of Rare Treatments Act (EXPERRT Act), championed by the CF Foundation, as part of a legislative package to reauthorize the U.S. Food and Drug Administration's (FDA) system for evaluating new prescription drugs and devices.
Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Drugs
206 care center directors sign a letter citing clinical consequences if decision moves forward.
Las personas con fibrosis quística y sus familias se han enfrentado a importantes cargas económicas debido a los programas acumuladores de copago. Familiarícese con estos programas y lo que implican para usted y sus seres queridos.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
People with cystic fibrosis and their families have faced significant cost burdens due to copay accumulator programs. Get caught up on these programs and what they mean for you and your loved ones.
The law signals major improvements in health care affordability for people with CF.
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.